Carisma Therapeutics (CARM) - 2023 Q4 - Annual Results

Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Other prioritized pipeline programs include the Company's in vivo CAR-M collaboration with Moderna, and research programs including fibrosis PHILADELPHIA – April 1, 2024 – Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today reported financial results for the fourth qu ...